2 multi-bagging growth stocks I’d buy for 2018

It looks like 2018 could be a great year for growth investors. Here are two high-flying stocks for you to check out.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It can be hard plucking up the courage to invest in a stock that has already multi-bagged, but sometimes they just keep going up.

Shares in Clinigen Group (LSE: CLIN) have more than four-bagged over the past five years, as earnings have been growing in double-digits every year. The year to June 2017 brought in a 25% rise, and analysts are predicting 13% this year followed by 19% next.

I was happy to read the company’s first-half trading update on Wednesday, which told us that the first half has been “in line with the board’s expectations.” Revenues are up by around 28%, with gross profit up by about 10% — the latter is, apparently, the board’s preferred measure of top-line growth.

So I was surprised to see the share price down by 3% at the time of writing, to 1,003p. But I guess that’s part of the fickleness of a high-flying growth stock, which can falter when figures fail to beat expectations.

Excellent growth

The highlight was the company’s Commercial Medicines division, which apparently accounts for 49% of gross profit, and which “delivered excellent growth, with all products across the portfolio performing strongly.

Unlicensed Medicines, representing 41% of gross profit, seems to have had a mixed time, but “a significant number of new programmes now starting” are expected to boost performance in the second half.

The Clinical Trial Services business, with 10% of gross profit, saw its performance fall back from last year’s, and that might also have contributed to the morning’s sell-off. But Clinigen says it should do better in the second half.

On current growth forecasts we’re looking at a forward P/E of 21 for June 2018, dropping to 18 on 2019 expectations. Dividends are currently yielding only around 0.5%, but they’re very well covered and strongly progressive.

And even though the share price has already climbed, I’m still seeing an attractive long-term valuation here.


Shares in JD Sports Fashion (LSE: JD) have done even better, 10-bagging in five years. And even after that, with the shares at 390p, we’re still only looking at forward P/E multiples of 13 to 15, which is around the FTSE 100‘s long-term average.

Admittedly there’s not much in the way of dividend cash right now, with yields similar to Clinigen’s 0.5% level. But we’re looking at cover of around 14 times by earnings, and I can see the company morphing into a solid cash cow in future years.

Tuesday’s update which covered the Christmas trading period impressed me, especially when so many other retailers have been feeling the high-street pinch. And instead of falling earnings that some are now predicting, JD has upped its full-year pre-tax profit guidance to £300m, ahead of the market’s £270m-£295m prior consensus.

Online business is expanding too, and I’m becoming more and more convinced that the retail future will belong to companies that combine internet sales with physical stores — the demand for the ability to collect and/or return goods in-store is growing.

Though I don’t pay much attention to share price charts, I am drawn to the fact that JD shares are still significantly below their May 2017 peak of over 450p — I thought the shares were fair value then, and now I reckon I’m seeing a bargain. The year ends 31 January, with results due 17 April.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Clinigen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »

Investing Articles

£13,200 invested in this defensive stock bags me £1K of passive income!

Building a passive income stream is possible and this Fool breaks down one investment in a single stock that could…

Read more »

Investing Articles

I think the Rolls-Royce dividend is coming back – but when?

The Rolls-Royce dividend disappeared in 2020 and has not come back. But with the company performance improving, might it reappear?

Read more »

British Pennies on a Pound Note
Investing Articles

Should I snap up this penny share in March?

Our writer is considering penny shares to buy for his portfolio next month. Does this mining company merit a place…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Stock market bubble – or start of a bull run?

Christopher Ruane considers whether the surging NVIDIA share price could be symptomatic of a wider stock market bubble forming.

Read more »

Investing Articles

Buying 8,254 Aviva shares in an empty ISA would give me a £1,370 income in year one

Harvey Jones is tempted to add Aviva shares to his Stocks and Shares ISA this year. Today’s 7.37% yield isn't…

Read more »

Investing Articles

Is the tide turning for bank shares?

Bank shares are trading on stubbornly cheap-looking valuations yet business performance in the sector is broadly robust. Should our writer…

Read more »